한․양방 협진에 의한 만성 B형 간염 환자에서의 HBV-DNA 감소 증례보고
HBV-DNA Suppression in a Chronic Hepatitis B Patient Treated with Western Medicine Plus Traditional Korean Medicine Combination Therapy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Here we describe a case of lamivudine and entecavir resistant chronic hepatitis B, treated with western medicine plus traditional korean medicine combination therapy. We administered Injinchunggan-Tang(茵蔯淸肝湯), a traditional Korean herb remedy, with entecavir to a 45-year-old chronic hepatitis B patient who didn't have achieved HBV-DNA suppression, in spite of 18 month lamivudine mono therapy and 14 month entecavir mono therapy. HBV-DNA decreased more than one thousandth from 98,100 IU/mL to 53 IU/mL just in 23 days, and resultingly it seems that the combination therapy could be very potent, at least to some chronic hepatitis B patients.
Abstract
Here we describe a case of lamivudine and entecavir resistant chronic hepatitis B, treated with western medicine plus traditional korean medicine combination therapy. We administered Injinchunggan-Tang(茵蔯淸肝湯), a traditional Korean herb remedy, with entecavir to a 45-year-old chronic hepatitis B patient who didn't have achieved HBV-DNA suppression, in spite of 18 month lamivudine mono therapy and 14 month entecavir mono therapy. HBV-DNA decreased more than one thousandth from 98,100 IU/mL to 53 IU/mL just in 23 days, and resultingly it seems that the combination therapy could be very potent, at least to some chronic hepatitis B patients.
참고문헌 (23)
- 신정우, "만성 B형 간염 치료", 대한내과학회지, 77(3), pp.265~274 (2009), 대한내과학회
- Lok, A.S., "Chronic hepatitis B: update 2009", Hepatology, 50(3), pp.661~662 (2009)
- Chang, T.T., "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354(10), pp.1001~1010 (2006)
- Tenney, D.J., "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49(5), pp.1503~1514 (2009)
- Zhang, L., "Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review", Hepatology, 51(2), pp.690~698 (2010)
- 채우석, "동씨기혈집성", pp.251~255 (1997), 일중사
- 전국 한의과대학 간계내과학교수 공저, "간계내과학 4판", pp.256~290 (2001), 동양의학연구원
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50(2), pp.227~242 (2009)
- Dienstag, J.L., "Lamivudine as initial treatment for chronic hepatitis B in the United States", New Engl J Med, 341(17), pp.1256~1263 (1999)
- Lai, C., "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339(2), pp.61~68 (1998)
- Schalm, S.W., "Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial", Gut, 46(4), pp.562~568 (2000)
- Chang, T.T., "Four years of lamivudine treatment in Chinese patients with chronic hepatitis B", J Gastroenterol Hepatol, 19(11), pp.1276~1282 (2004)
- Lok, A.S., "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125(6), pp.1714~1722 (2003)
- Hadziyannis, S., "Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years", Gastroenterology, 131(6), pp.1743~1751 (2006)
- Marcellin, P., "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359(23), pp.2442~2455 (2008)
- Chang, T.T., "comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354(10), pp.1001~1010 (2006)
- Lai, C.L., "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354(10), pp.1011~1020 (2006)
- Sherman, M., "Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)", Gastroenterology, 130(Suppl 2), pp.A765~ (2006)
- Tenney, D.J., "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49(5), pp.1503~1514 (2009)
- 김동준, "Telbivudine versus lamivudine in patients with chronic hepatitis B", NEW ENGLAND JOURNAL OF MEDICINE, 357(25), pp.2576~2588
- Lim, S.G., "A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B", Arch Intern Med, 166(1), pp.49~56 (2006)
- Yoo, B.C., "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B", HEPATOLOGY, 45(5), pp.1172~1178 (2007), JOHN WILEY & SONS INC
- Ferrucci, L.M., "Complementary and alternative medicine use in chronic liver disease patients", J Clin Gastroenterol, 44(2), pp.e40~45 (2010)